Literature DB >> 14604617

Optimisation versus certainty: understanding the issue of heterogeneity in economic evaluation.

Warren Stevens1, Charles Normand.   

Abstract

This paper considers how the information provided by economic evaluation for decision-makers can fail to optimise use of health resources and how assessment of the relative cost-effectiveness of health care interventions can be misleading unless heterogeneity within populations is taken into account. The cost-effectiveness of an intervention is not a point estimate but an average chosen from within a distribution of different results. The normal interpretation of the distribution around that point is often mistakenly assumed to be the 'white noise' of measurement error. In reality this variance is a combination of measurement error and true heterogeneity of results. There remains an overemphasis on pursuing certainty which stems from the fact that the methods involved were originally devised to measure dichotomous outcomes not continuous ones such as cost-effectiveness ratios. It is argued in this paper that more consideration be given to the heterogeneous nature of costs and effects across populations in analysis and policy making.

Mesh:

Year:  2004        PMID: 14604617     DOI: 10.1016/s0277-9536(03)00215-6

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  8 in total

1.  From Pharmacovigilance to Clinical Care Optimization.

Authors:  Leo Anthony Celi; Edward Moseley; Christopher Moses; Padhraig Ryan; Melek Somai; David Stone; Kai-Ou Tang
Journal:  Big Data       Date:  2014-09-01       Impact factor: 2.128

2.  Racial variation in the cost-effectiveness of chemotherapy for prostate cancer.

Authors:  Michael Grabner; Eberechukwu Onukwugha; Rahul Jain; C Daniel Mullins
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

Review 3.  Acknowledging patient heterogeneity in economic evaluation : a systematic literature review.

Authors:  Janneke P C Grutters; Mark Sculpher; Andrew H Briggs; Johan L Severens; Math J Candel; James E Stahl; Dirk De Ruysscher; Albert Boer; Bram L T Ramaekers; Manuela A Joore
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

4.  Biases in Individualized Cost-effectiveness Analysis: Influence of Choices in Modeling Short-Term, Trial-Based, Mortality Risk Reduction and Post-Trial Life Expectancy.

Authors:  David van Klaveren; John B Wong; David M Kent; Ewout W Steyerberg
Journal:  Med Decis Making       Date:  2017-03-20       Impact factor: 2.583

5.  Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants.

Authors:  Ahva Shahabi; Desi Peneva; Devin Incerti; Kimmie McLaurin; Warren Stevens
Journal:  Pharmacoecon Open       Date:  2018-03

6.  The economic case for precision medicine.

Authors:  Sean P Gavan; Alexander J Thompson; Katherine Payne
Journal:  Expert Rev Precis Med Drug Dev       Date:  2018-01-08

7.  A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-Health Impacts and Distributional Issues.

Authors:  Meghan I Podolsky; Isabel Present; Peter J Neumann; David D Kim
Journal:  Value Health       Date:  2022-04-06       Impact factor: 5.101

8.  The value of heterogeneity for cost-effectiveness subgroup analysis: conceptual framework and application.

Authors:  Manuel A Espinoza; Andrea Manca; Karl Claxton; Mark J Sculpher
Journal:  Med Decis Making       Date:  2014-06-18       Impact factor: 2.583

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.